Evotec AG today announced that it has entered into a research collaboration with the Center for Regenerative Therapies TU Dresden („CRTD“) to discover novel small molecule candidates for retinal diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-into-research-collaboration-with-crtd-to-discover-novel-therapies-for-retinal-diseases-5652